Evidence map›Paper›PMID 41332109›Full record

Trial reportZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2025

[Performance evaluation of different filtration fractions during daytime continuous renal replacement therapy].

Li Wang, Yanxia Chen, Gaosi Xu, Chengyun Xu

Abstract readRandomized Controlled TrialEnglish Abstract
In one paragraph

Trial report in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Li WangDepartment of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China. h409443290@163.com.
Yanxia ChenDepartment of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China.
Gaosi XuDepartment of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China.
Chengyun XuDepartment of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China. 1147202241@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the effects of different filtration fractions (FFs) during continuous venovenous hemodiafiltration (CVVHDF) post-dilution.

methodsThis study employed a single-blind, head-to-head randomized controlled design. Patients who underwent daytime continuous renal replacement therapy (CRRT) in the Department of Nephrology, the Second Affiliated Hospital of Nanchang University between April 2022 and June 2023 were prospectively enrolled. They were randomly assigned to either a low FF group (FF set at 20%-<25%) or a high FF group (FF set at 25%-30%). All patients received post-dilution CVVHDF with systemic heparin anticoagulation. The primary outcome was extracorporeal circuit coagulation, comprehensively assessed through dynamic monitoring of arterial pressure, venous pressure, and transmembrane pressure, combined with filter clotting grading at the end of the session. Secondary outcomes included changes in serum creatinine, urea, potassium, and pH levels before and after treatment to evaluate efficacy.

resultsA total of 40 patients were included in both the low FF group and the high FF group. The baseline characteristics showed no statistically significant differences between the two groups (all

conclusionsFor patients with a relatively short treatment duration of 10-12 h undergoing post-dilution CVVHDF, employing an FF of 25%-30% does not pose a higher risk of extracorporeal circuit coagulation compared to an FF of 20%-<25%, but shows higher creatinine clearance.

Indexed as

Acute Kidney InjuryContinuous Renal Replacement TherapyHemodiafiltrationAdultAgedCreatinineFemaleHumansMaleMiddle AgedProspective StudiesSingle-Blind MethodCreatinineContinuous renal replacement therapyEfficacyExtracorporeal circuit coagulationFiltration fraction

Identifiers

PMID41332109
PMCPMC12750054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.